Skip to main content

Table 1 Studies comparing IC and IV administration of abciximab in patients with STEMI

From: Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration

Author Year* Design Patients No In favor of Main results
Wohrle et al [34] 2003 retrospective STEMI/NSTEACS 403 IC reduced incidence of MACE at 30 days
Bellandi et al [27] 2004 prospective, randomized STEMI 45 IC higher salvage index and LV functional recovery (serial gated SPECT)
Romagnoli et al [32] 2005 prospective, matched STEMI/NSTEACS 74 IC increased coronary flow (cTFC)
Galache et al [29] 2006 prospective, randomized STEMI/NSTEACS 137 neutral no difference in the incidence of MACE at 1 year
Thiele et al [33] 2008 prospective, randomized STEMI 154 IC reduced infarct size and extent of MO (MRI at 2 days)
Dominguez-Rodriguez et al [28] 2009 prospective, randomized STEMI 50 IC larger reduction in soluble CD40 ligand
  1. * Year of publication
  2. cTFC: corrected TIMI frame count; IC: intracoronary; IV: intravenous; MACE: major adverse cardiac event; MO: microvascular obstruction; MRI: magnetic resonance imaging; No: number of patients; NSTEACS: non-ST-elevation acute coronary syndrome; SPECT: single photon emission computed tomography; STEMI: ST-segment elevation myocardial infarction